Brought to you by 
Aptinyx brings in $65mm via Series A round
26 May 2016
Executive Summary
Aptinyx Inc. (N-methyl-D-aspartic acid (NMDA) receptor modulators for neurological disorders) raised $65mm in a Series A round led by New Leaf Venture Partners, which was joined by other new backers Frazier Healthcare Partners, Longitude Capital, and Osage University Partners; other participants included returning seed investors Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O'Keefe & Co., and Northwestern University. New Leaf, Frazier, and Longitude added members to the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aptinyx brings in $65mm via Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice